New hope for drug-resistant stomach cancer: sorafenib shows promise in early trial
NCT ID NCT00265798
First seen May 02, 2026 · Last updated Jun 08, 2026 · Updated 6 times
Summary
This study tested the drug sorafenib in 38 people with advanced gastrointestinal stromal tumor (GIST) that had stopped responding to two standard treatments, imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumor cells grow and by cutting off blood supply to the tumor. The main goal was to see if the drug could shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62702, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Decatur Memorial Hospital
Decatur, Illinois, 62526, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.